Prescription of oral antidiabetic drugs in Tyrol – Data from the Tyrol diabetes registry 2012–2015

Abstract

SummaryDiabetes mellitus affects 9% of the adult population worldwide and the economic burden of the disease is growing exponentially. In type 2 diabetes mellitus (T2DM), when life style interventions fail to achieve treatment targets, oral antidiabetic drugs are prescribed to improve glycemic control. Several new oral antidiabetics have been launched in the last few years, which enlarged the spectrum of available treatment options in T2DM. The present study aimed to examine T2DM treatment patterns in a cohort of 7769 patients recruited from the Diabetes Registry Tyrol (DRT) with at least one visit from 2012–2015. Secondly, the study aimed to evaluate the use of new oral antidiabetics compared to older oral antidiabetics (OAD). It was found that 43.4% of all patients were treated with OAD alone while 21.2% had oral antidiabetics combined with insulin. 19.9% of the study population were treated with insulin or insulin analogs only. 15.3% had no pharmacological treatment. Metformin was used most frequently (47.9% of the study population), followed by gliptines (27.2%). The most common treatment regimen in this population was the dual therapy of metformin and another OAD (17.2%), followed by metformin monotherapy (16.6%) and triple therapy of metformin and two additional OAD (11.0%).

Regional differences in type 2 diabetes treatment and outcomes in Germany—An analysis of the German DPV and DIVE registries

“…Compared with our data, OADs were prescribed more often, while the combination of OAD and insulin was less common 36. In contrast, data on antihyperglycaemic medication from Germany are more similar to the prescription habits in Tyrol, based on an analysis of data from the Tyrol diabetes registry 37. In this study, among all Oral anti-diabetic drugs alone were used in 43.4% of all patients, followed by OAD combined with insulin (21.2%), while use of insulin alone (human insulin and insulin analogues) was prescribed in 19.9% of patients.…”

“…In contrast, data on antihyperglycaemic medication from Germany are more similar to the prescription habits in Tyrol, based on an analysis of data from the Tyrol diabetes registry . In this study, among all OADs prescribed, metformin was the most frequent (47.9%), followed by gliptins (27.2%), sulfonylurea (13.5%), glitazones (3.7%), SGLT2 inhibitors (3.7%), GLP‐1 analogues (1.1%), and glucosidase inhibitors (0.4%).…”

Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018

“…[34][35][36][37][38] Since the last DRT publication data have shown that metformin is now the most prevalent antidiabetic medication throughout every age group. 28 Approval in CKD, decreased CV mortality in monotherapy and combination therapy, same glycemic results as glitazones and sulfonylureas, higher effectiveness than gliptins, increasing long-term data and physician experience made metformin applicable to all age groups and substantiated the increase in use of metformin in the treatment of type 2 diabetes. 32 33 39 Clinical care/Education/Nutrition…”

Untitled

“…[22] The most common treatment regimen in this population was the dual therapy of metformin and another OAD (17.2%), followed by metformin monotherapy (16.6%) and triple therapy of metformin and two additional OAD (11.0%). [12] In our research, the higher consumption rates of OAD were received for such combinations as glibenclamide with metformin and glimepiride with metformin.…”

“…[10] Likewise, the most prescribed medications according to research of Gaviria-Mendoza et al [11] were metformin 81.3%, insulins 3.3%, and sulfonylureas 21.8%. Lunger et al [12] presented results of research where metformin was used most frequently (47.9% of the study population), followed by gliptines (27.2%). Results of research in Australia also confirmed 5-fold increasing of metformin utilization between 1995 and 2012.…”